Michail Ignatiadis
Institut Jules Bordet, Belgium · Jules Bordet Institute · Medical Oncology Department
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michail Ignatiadis as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:54 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05512364 · Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)European Organisation for Research and Treatment of Cancer - EORTC · recruiting · ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer · study chair
- Ph2NCT03065621 · Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)Jules Bordet Institute · completed · Breast Cancer Female · study chair
- Ph2NCT02338531 · Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncerJules Bordet Institute · withdrawn · Breast Cancer · study director
- Ph2NCT01548677 · Efficacy Study of Herceptin to Treat HER2-negative CTC Breast CancerEuropean Organisation for Research and Treatment of Cancer - EORTC · completed · Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Circulating Tumor Cells · principal investigator
- Ph2NCT01537536 · Trial of Neoadjuvant EndoTAG-1 in Combination With Paclitaxel in HER2-negative Breast CancerJules Bordet Institute · completed · Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:54 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:54 UTC. The ranking covers the 200 most relevant of 16 PubMed records, and a shared surname and initials can bring in a namesake. All 16 on PubMed
- Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.J Natl Cancer Inst · 201978 citationsRCR 3.0
- Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy.J Natl Cancer Inst · 201974 citationsRCR 2.3
- 59 citationsRCR 2.5
- 56 citationsRCR 1.8
- 35 citationsRCR 2.6
- 34 citationsRCR 0.8
- First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.J Immunother Cancer · 202325 citationsRCR 1.8
- 24 citationsRCR 0.9
- The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.JAMA Oncol · 201623 citationsRCR 0.6
- Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.Eur J Cancer · 202221 citationsRCR 1.2